Gilead Sciences (GILD) Estimates Trimmed at Needham & Company Post Q4; 'Buy' Maintained

Gilead Sciences (GILD) Commentary Does Little to Quell Fears But Stock Undervalued - Cowen

Cowen analyst Phil Nadeau maintained an Outperform rating and $125 price target on Gilead Sciences (NASDAQ: GILD) following solid Q4 results, in-line 2015 sales guidance but commentary that did little to quell fears.

Nadeau commented, "GILD reported Q4:14 HCV sales ahead of consensus, and provided... More

Gilead (GILD) Price Target Lowered to $118 at RBC Capital

RBC Capital maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) and lowered its price target to $118.00 (from $125.00). The change follows Q4 results. Overall analyst Michael J. Yee thinks the stock is cheap, with lots of optionality.

" ...GILD spooked investors with 2015 HCV guidance of "gross-to-net" rebates of 46%, which was higher than consensus 30%+, implying net pricing lower and competitive deals to... More

Gilead Sciences (GILD) PT Trimmed to $116 at Piper Jaffray as Guidance was a Letdown

Piper Jaffray analyst Joshua Schimmer weighed in on Gilead Sciences (NASDAQ: GILD) following solid Q4 results but noted guidance was a letdown. The firm maintained an Overweight rating and trimmed its price target to $116.00 (from $120.00).

Schimmer commented, "GILD reported a solid 4Q... More

Goldman Sachs Lowers Its Price Target on Gilead (GILD) to $85

Goldman Sachs maintained a Neutral rating on Gilead Sciences (NASDAQ: GILD) and lowered its price target to $85.00 (from $96.00). The change follows Q4 results. Analyst Terence Flynn noted HepC pricing dynamics surprised to the downside.

"GILD guided to a 46% gross-to-net on US hepC pricing in 2015 (vs.... More

Gilead Sciences (GILD) PT Trimmed to $141 at Nomura Posts Q4

Nomura Securities analyst M. Ian Somaiya trimmed his price target on Buy-rated Gilead Sciences (NASDAQ: GILD) to $141.00 (from $146.00) following results after the close.

Somaiya commented, "We expect the shock of aggressive discounting by Gilead (46% vs. our 20% estimate) on its HCV drugs to lead to... More

Baird 'Incrementally Negative' on Gilead (GILD) Following Call

Baird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) saying they are incrementally negative following 4Q14 earnings call.

Skorney commented, "A sizeable beat, new dividend and massive share buyback program aren't enough to offset the disappointment in... More

Gilead Sciences (GILD) Approves Dividend Program; Adds $15B to Buyback Authorization

Gilead Sciences (NASDAQ: GILD) announced that the companys Board of Directors has authorized a dividend program under which the company intends to pay quarterly dividends of $0.43 per share, beginning in the second quarter of 2015, subject to quarterly declarations by the Board of Directors.

The Board of Directors also approved the... More

Gilead Sciences (GILD) Tops Q4 EPS by 22c; Approves Dividend Program, $15B Buyback

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $2.43, $0.22 better than the analyst estimate of $2.21. Revenue for the quarter came in at $7.31 million versus the consensus estimate of $6.68 million.

Product Sales

Total product sales for the fourth quarter of 2014 were $7.2 billion compared to $3.0 billion for the fourth quarter of 2013. In the fourth quarter, product sales in the U.S. were $5.5 billion compared to $1.9 billion in the fourth quarter of 2013, and in Europe, product sales were $1.4 billion compared to $871 million in the fourth quarter of 2013.... More